Literature DB >> 10504469

Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade.

Y Terada1, S Inoshita, O Nakashima, M Kuwahara, S Sasaki, F Marumo.   

Abstract

Mitogen-activated protein kinases (MAPKs) have been shown to play an important role in transducing extracellular signals into cellular responses. The classic MAPK pathway is commonly activated by growth factors and has been shown to play a crucial role in cell proliferation. Transforming growth factor-beta (TGF-beta)-activating kinase-1 (TAK1) is a novel MAPK kinase kinase that is reported to stimulate the MKK6-p38K pathway. To elucidate the functional roles of the TAK1 pathway, we transfected its constitutive active form (TAKdN) and negative form (TAKK63W) to LLC-PK1 cells. TAKdN stimulated MKK6 phosphorylation and p38K activity and inhibited the percentages of the S and G2/M phases. TAKK63W, the constitutive negative form, reduced TGF-beta-stimulated MKK6 phosphorylation and p38K activity and increased the percentages of the S and G2/M phases. The cyclin D1 protein level is reduced by the TAK1 pathway. We also examined the effects of the TAK1 pathway on cyclin D1 promoter-luciferase assay. The overexpression of TAKdN or p38K inhibited cyclin D1 promoter activity. In contrast, overexpression of the active form of MKK1, the classic MAPK-activator, MKK1 increased cyclin D1 promoter activity and protein level, as well as the percentages of S and G2/M phases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504469     DOI: 10.1046/j.1523-1755.1999.00704.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

Review 1.  Role of ischaemic preconditioning in liver regeneration following major liver resection and transplantation.

Authors:  D Gomez; S Homer-Vanniasinkam; A M Graham; K R Prasad
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

2.  Acquired resistance to rechallenge injury in rats that recovered from mild renal damage induced by uranyl acetate: accelerated proliferation and hepatocyte growth factor/c-Met axis.

Authors:  Yuan Sun; Yoshihide Fujigaki; Masanori Sakakima; Tomoyuki Fujikura; Akashi Togawa; Yanjie Huang; Akira Hishida
Journal:  Clin Exp Nephrol       Date:  2011-04-21       Impact factor: 2.801

3.  Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells.

Authors:  Parisa Ziasarabi; Amirhossein Sahebkar; Faezeh Ghasemi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism.

Authors:  Oded Volovelsky; Gili Cohen; Ariel Kenig; Gilad Wasserman; Avigail Dreazen; Oded Meyuhas; Justin Silver; Tally Naveh-Many
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

5.  Direct estradiol and diethylstilbestrol actions on early- versus late-stage prostate cancer cells.

Authors:  Luke Y Koong; Cheryl S Watson
Journal:  Prostate       Date:  2014-09-11       Impact factor: 4.104

6.  Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation.

Authors:  Yuben P Moodley; Amelia K Scaffidi; Neil L Misso; Carmel Keerthisingam; Robin J McAnulty; Geoff J Laurent; Steven E Mutsaers; Philip J Thompson; Darryl A Knight
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

7.  MKP1-dependent PTH modulation of bone matrix mineralization in female mice is osteoblast maturation stage specific and involves P-ERK and P-p38 MAPKs.

Authors:  Chandrika D Mahalingam; Bharat Reddy Sampathi; Sonali Sharma; Tanuka Datta; Varsha Das; Abdul B Abou-Samra; Nabanita S Datta
Journal:  J Endocrinol       Date:  2013-02-25       Impact factor: 4.286

8.  MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.

Authors:  Vivek Verma; Nazli Jafarzadeh; Shannon Boi; Subhadip Kundu; Zhinuo Jiang; Yiping Fan; Jose Lopez; Rahul Nandre; Peng Zeng; Fatmah Alolaqi; Shamim Ahmad; Pankaj Gaur; Simon T Barry; Viia E Valge-Archer; Paul D Smith; Jacques Banchereau; Mikayel Mkrtichyan; Benjamin Youngblood; Paulo C Rodriguez; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2020-11-23       Impact factor: 25.606

9.  A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis.

Authors:  Seung-Ah Yoo; Sungyong You; Hyung-Ju Yoon; Dong-Ho Kim; Hyun-Sook Kim; Kyungho Lee; Jin Hee Ahn; Daehee Hwang; Amy S Lee; Ki-Jo Kim; Yune-Jung Park; Chul-Soo Cho; Wan-Uk Kim
Journal:  J Exp Med       Date:  2012-03-19       Impact factor: 14.307

10.  Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Authors:  Sonya C Tate; Teresa F Burke; Daisy Hartman; Palaniappan Kulanthaivel; Richard P Beckmann; Damien M Cronier
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.